An experimental drug is showing promise in slowing early Alzheimer’s disease by targeting the tau protein, a novel approach compared to current treatments, researchers reported on Tuesday. While existing drugs like lecanemab and donanemab focus on clearing amyloid protein buildup to modestly slow cognitive decline, previous attempts to develop tau-targeting drugs have largely failed.
However, new findings presented at the Alzheimer's Association International Conference in London suggest Biogen's diranersen not only reduced tau levels but also indicated a slowdown in cognitive decline. In a small subset of the 400-person study, this effect was comparable to amyloid therapies. Biogen is now planning a larger trial to confirm these benefits.
